KODIAK SCIENCES INC. FORWARD-LOOKING STATEMENTS ts” within the meaning ntains “forward-looking statements This Annual Report con 21E of the Securities e Securities Act of 1933, Section 2 of Section 27A of the n Reform Act of 1995. nd the Private Securities Litigation Exchange Act of 1934 an ical fact and include statements are not based on histori These forward-looking s study readouts; the the expected timing of clinical st statements regarding: t trials; the potential oints in our four ongoing Phase 3 t ability to meet all endpo achieve a greater -in-class bispecific ABC and to for KSI-501 to be a first- otent inhibition of certain patients and to provide po therapeutic benefit for ce ted inflammation; cular permeability and IL-6 mediat both VEGF-mediated vasc ans; our progress GF market; future development pla the growth of the anti-VEG and anticipated capability to support our clinical activating manufacturing f our tarcocimab jectives and potential benefits of commercial needs; the obj treatment and g its potential to enable earlier clinical program, including es, the potential r patients with diabetic eye disease prevention of vision loss for lated economic a year dosing, and the potential re for effectiveness with twice investigational f the global rights to all of our opportunity; the value of with alternate platforms; our ability to compete medicines and technology nd future cash and the strength of our current a technologies and biologics; ments that are tatements generally include statem positions. Forward-looking st s or conditions, pend upon or refer to future events predictive in nature and dep ould,” “expect,” “may,” “will,” “should,” “would,” “co and include words such as “ ssions among pursue,” and other similar expres “plan,” “believe,” “intend,” “p ment’s current statements are based on managem others. Any forward-looking s ertainties that s and are subject to a risks and unc expectations of future events om those in or differ materially and adversely fro could cause actual results to uncertainties king statements. These risks and implied by such forward-loo al studies and/ o: cessation or delay of any clinica include, but are not limited t risk that KSI- ab and/or KSI-501 may occur; the or development of tarcocima ity or have an nd IL-6, provide extended durabili 501 may not inhibit VEGF an at tarcocimab patients as expected; the risk tha impact on the treatment of ss for patients ment and prevention of vision los may not enable earlier treat ory milestones expected; future potential regulato with diabetic eye diseases as lanned clinical ding those related to current and p of tarcocimab/KSI-501, includ ns or approval; to support regulatory submission studies, may be insufficient business and ns may significantly impact our adverse economic condition manufacturers, nical trial sites, and those of our m operations, including our cli uct business; as ons or others with whom we condu contract research organizatio s and Exchange ied in our filings with the Securities well as the other risks identif nties, and other cussion of other risks and uncertain Commission (SEC). For a disc ts to differ from hich could cause our actual result important factors, any of wh section entitled ward-looking statements, see the s those contained in the forw ions of potential ecent Form 10-K, as well as discuss “Risk Factors” in our most re quent filings with her important factors in our subseq risks, uncertainties, and oth f the date hereof oking statements speak only as of the SEC. These forward-loo oking statements, o obligation to update forward-loo and Kodiak undertakes no on such forward- ed not to place undue reliance o and readers are cautione BC Platform™ and ak®, Kodiak Sciences®, ABC™, AB looking statements. Kodia of Kodiak Sciences stered trademarks or trademarks o the Kodiak logo are regis isdictions. Inc. in various global juris